Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 11, 2020

Janssen’s lung cancer drug gets FDA breakthrough status

Janssen Pharmaceutical has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for JNJ-61186372 (JNJ-6372) to treat metastatic non-small cell lung cancer (NSCLC).

Janssen Pharmaceutical has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for JNJ-61186372 (JNJ-6372) to treat metastatic non-small cell lung cancer (NSCLC).

The drug is for patients having epidermal growth factor receptor (EGFR) Exon 20 insertion mutations and who have progressed on or following platinum-based chemotherapy.

JNJ-6372 is an EGFR-mesenchymal-epithelial transition factor (MET) bispecific antibody designed to act on activating and resistant EGFR and MET mutations and amplifications.

FDA is yet to approve a drug for lung cancer patients with EGFR Exon 20 insertion mutations.

Janssen Research & Development Oncology global therapeutic area head Peter Lebowitz said: “JNJ-6372 is a novel bispecific antibody that we believe has the potential to benefit patients with Exon 20 mutation insertions who often do not respond to currently available oral EGFR-targeted or immune checkpoint inhibitor therapies.

“This breakthrough therapy designation is a significant milestone in our ongoing efforts to advance JNJ-6372 in clinical development and target genetically-defined lung cancer.”

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

The FDA designation comes from results of an open-label, multi-centre Phase I clinical trial that assessed safety, pharmacokinetics and preliminary efficacy of JNJ-6372 as a monotherapy and also in combination with lazertinib.

Janssen licensed lazertinib, an EGFR TKI, from Yuhan Corporation in 2018.

The Phase I trial establishes the recommended Phase II dose in patients with advanced non-small cell lung cancer. Patient recruitment into part two dose-expansion cohorts is ongoing.

Currently, the trial is assessing the activity of JNJ-6372 as monotherapy in different NSCLC sub-populations with genomic alterations, including C797S resistance mutation or MET amplification.

In January, Janssen received extended approval from the European Commission (EC) for Erleada (apalutamide) combined with androgen deprivation therapy (ADT) to treat adults with metastatic hormone-sensitive prostate cancer (mHSPC).

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU